• Sign Up

Superficial Thrombophlebitis


Superficial Thrombophlebitis

Article Author:
Augusta Czysz
Article Editor:
Sheetal Higbee
Updated:
3/16/2020 1:08:14 PM
For CME on this topic:
Superficial Thrombophlebitis CME
PubMed Link:
Superficial Thrombophlebitis

Introduction

Superficial thrombophlebitis is an inflammatory disorder of superficial veins with coexistent venous thrombosis.[1][2] It usually affects lower limbs, particularly the great saphenous vein (60% to 80%) or the small/short saphenous vein (10% to 20%). However, it can occur at other sites (10% to 20%) and may occur bilaterally (5% to 10%).[3][4] Traditionally, this relatively common process was considered benign and self-limited. More recently, superficial thrombophlebitis, also called superficial venous thrombosis (SVT), has been associated with other venous thromboembolic disorders, primarily deep venous thrombosis (DVT) and pulmonary embolism (PE). Therefore, it involves more than a purely clinical diagnosis with supportive treatment.[1][2][3][4][5] Affected patients have an increased risk for recurrence of venous thromboembolic events.[4] Herein, the terms of superficial thrombophlebitis and superficial venous thrombosis will be used interchangeably.

Etiology

Hypercoagulable state, prolonged immobilization, or vessel wall trauma may increase the risk of SVT. Superficial thrombophlebitis accounts for 5.4% of the adjusted population attributable risk for initial DVT or PE. SVT has been the presenting symptom in certain inheritable thrombophilias. It occurs in 11% to 15% of patients with protein C or S deficiency and approximately 40% of patients with factor V Leiden mutation according to several studies.[5] However, another study showed that these results were not statistically significant.[6] 

In pregnancy, the risk of SVT is akin to that of DVT, most commonly in the postpartum period. Advanced age, exogenous estrogens, autoimmune or infectious diseases, obesity, recent trauma or surgery, active malignancy, history of venous thromboembolic disease, and respiratory or cardiac failure also increase the risk of SVT.[2][3][4][6] Prior occurrences increase the risk of subsequent ones. As noted in 75% to 88% of cases, varicose veins are considered the most important clinically identifiable predisposing factor for SVT.[2][3][4][5][6]

Epidemiology

The true incidence of superficial thrombophlebitis is unclear. In France, one community-based study noted the incidence of SVT to be 0.64%, while a different community-based study found the incidence to be half that of DVT and similar to that of PE.[3][6] Other studies suggest its prevalence in the general population is two to six times higher than the incidence of DVT and PE.[2][4][6] SVT is commonly seen in the outpatient population; usually women, who made up 50% to 70% of the affected patients in one study; 60 years mean age; a body mass index that exceeds 25 kg/m2; and in those with varicose veins.[2][3][6]

For people who have a history of SVT, the lifetime risk of DVT or PE increases four to six times. While the three-month mortality is about 5% in patients with DVT or PE, it is less than 1% for those with SVT. One suggested reason for the lower mortality in patients with SVT is the younger age of the patients with fewer associated comorbidities.[3] The migration of the thrombus towards the deep veins at the saphenofemoral junction, the saphenopopliteal junction, or from a perforating vein during a state of hypercoagulability may cause the association between SVT and DVT or PE.[3][6] 

Pathophysiology

Superficial thrombophlebitis starts with microscopic thrombosis. When there is venous turbulence or stasis, vessel wall injuries, abnormal coagulability, or vessel wall injuries, microthrombi could propagate and then form macroscopic thrombi. Vascular endothelial injury reliably results in thrombus formation by triggering an inflammatory response that results in immediate platelet adhesion. Platelet aggregation is mediated by thrombin and thromboxane A2.

History and Physical

Patients with superficial thrombophlebitis typically present with a reddened, warm, inflamed, tender area overlying the track of a superficial vein. There is often a palpable cord. Some surrounding edema or associated pruritis may occur. Significant swelling of the limb is more commonly associated with DVT and should only be attributed to SVT after DVT has been excluded.[1][2][3][6][7] Patients may have a history of antecedent trauma, which can include intravenous cannulation or infusion of irritants, such as recent sclerotherapy for varicose veins.[2][8]

A careful history is critical to identify risk factors for venous thromboembolism. Initial presentation in patients older than 40 years without other risk factors should prompt consideration of underlying malignancy.[2][6] Patients with migratory thrombophlebitis, a well documented paraneoplastic phenomenon, should also be further evaluated for underlying malignancy.[2][6][9] Migratory thrombophlebitis is usually associated with pancreatic or other visceral malignancies and is often referred to as Trousseau syndrome. It can be the presenting complaint in 5% to 15% of pancreatic cancer, particularly of the body and tail.[6][9][10]

Evaluation

Traditionally, superficial thrombophlebitis was a clinical diagnosis. However, with the increased realization of association with concomitant DVT or PE, compressive ultrasonography is recommended.[2][5][6] Physical examination does not adequately identify the extent of disease; it has been shown to underestimate it in up to 77% of instances. Compressive ultrasonography can identify concomitant DVT, evaluate the extent of the thrombus, and confirm the diagnosis.[2][6] The Prospective Observational Superficial Thrombophlebitis (POST) study reviewed venous duplex screening of the affected lower limb and showed that 23.5% of patients had concurrent DVT. More than half of these DVTs were not contiguous with the SVT; 17% were noted to affect the contralateral lower extremity while only 1% had an isolated DVT in the contralateral limb. These findings support the regular use of ultrasound to evaluate SVT. The POST study also sought to establish the ultrasonic findings that increased the likelihood of associated DVT. It found that the risk substantially increased if a perforating vein was involved, with an odds ratio of 8.1, or if there was an SVT present less than 3 cm from the saphenofemoral junction, which had an odds ratio of 3.3.[6]

D-dimer testing is of limited utility in detecting SVT. It is variably elevated in SVT and, therefore, cannot be used to distinguish isolated SVT from DVT.[2]

Experts debate as to whether patients who present with extensive superficial thrombophlebitis without an apparent inciting reason should have an evaluation for thrombophilia given that hypercoagulability is associated with SVT. However, to date, there have been no conclusive studies identifying causation between hypercoagulability and SVT.[2]

As previously mentioned, migratory thrombophlebitis warrants evaluation for visceral neoplasm. Patients older than 40 years with their first episode of thrombophlebitis should also be evaluated for underlying neoplasm.[6][9] Superficial thrombophlebitis of the superficial breast veins is referred to as Mondor disease. A case series from 1992 noted a 12.7% risk of associated breast cancer, but it was a limited study, so it is argued that the incidence could have been overrepresented. Therefore, mammography could be considered in patients with this presentation.[6]

To help establish the pretest probability for the presence of DVT in patients with SVT, the Internal Carotid Artery Occlusion (ICARO) Study Group has outlined the following five variables: 

  • Active malignancy (1.5 points)
  • Limb edema (1.5 points)
  • Age of fifty years or more (1 point)
  • A ropelike sign (-1 point)
  • Unprovoked SVT (-1 point)[11]

The ICARO Study Group suggested this scoring system to help when assessing such patients for coexisting DVT:

  • Low probability (less than zero points): 1.1% likelihood
  • Intermediate probability (score of 0 to 1): 12.0% likelihood
  • High probability (scored 1.5 or more points): 32.3% likelihood[11]

However, a more recent study using this scoring system does not support its validity.[12]

Treatment / Management

Despite the number of studies performed, there is still debate on the appropriate treatment for superficial thrombophlebitis.

Multiple strategies have been proposed to control symptoms and decrease the extension of thrombosis and risk for PE in low-risk superficial thrombophlebitis.[2] Low-risk thromboses are those not associated with the presence of or predisposition to other thromboembolic diseases. In these cases, the consensus is that nonsteroidal anti-inflammatory agents, heat, and anticoagulants are all reasonable.[7]

Those who are at higher risk include patients with an SVT in the lower extremity that is at least 5 cm in length; SVT proximal to the knee, especially within 10 cm of the saphenofemoral junction; the presence of severe symptoms; greater saphenous vein involvement; previous SVT/venous thromboembolic disease; active malignancy; or recent surgery.[6] Based on the Cochrane review published in 2018, these patients should receive fondaparinux 2.5 mg/day subcutaneously for 45 days.[1]

This Cochrane review also evaluated topical and surgical treatments but noted that the data is too limited in regards to these treatments and their effects on venous thromboembolic disease, so further studies are recommended at this time.[1] Rivaroxaban 10 mg daily for 45 days was found to be non-inferior to fondaparinux in the prevention of venous thromboembolic complications with a comparable safety profile in the SURPRISE trial. However, the Cochrane review did recommend further research on its use as well as the other direct oral factor-X or thrombin inhibitors.[1][13] Additionally, it recommended further study on the use of nonsteroidal anti-inflammatory agents and low molecular weight heparins.[1]

In those patients who develop superficial thrombophlebitis from an infusion, multiple agents have been evaluated for treatment. Per the 2015 Cochrane review of this topic, there is no consensus recommendation on the safety, dose required, or duration of therapy for topical treatments, nonsteroidal anti-inflammatory agents, or systemic anticoagulation.[8]

Practices in the United Kingdom suggest the use of compression stockings with or without additional therapies, but there is no current recommendation for or against their use in the United States of America.[2][6]

Antibiotics are useful only with clear infection.[2]

For Trousseau syndrome, the main priority is to eliminate the underlying malignancy. However, as this is commonly a challenge, heparin is the recommended treatment given that multiple pathways contribute to the development of the thrombus. Low molecular weight heparins have been used, but some have been less effective than heparin; therefore, further studies are recommended. Fondaparinux has also been evaluated but found to be less efficacious than heparin, and the utility of this agent also requires further study.[9] A case report on the topic recommended the initial treatment with heparin followed by oral anticoagulants but did not specify a particular agent or dosing schedule.[10]

Mondor disease discussed separately, is usually self-limited and benign and will resolve in four to eight weeks. However, if it is due to vasculitis, malignancy, or a hypercoagulable state, treatment is aimed at the underlying cause.[14]

Differential Diagnosis

It is essential to keep superficial thrombophlebitis on the differential when evaluating a patient. Other considerations include cellulitis, other venous thromboembolic diseases, hematoma, lymphangitis, lymphedema, vasculitis, tendonitis or sports-related injuries, and venous insufficiency.[15][16][17][18][19]

Prognosis

The prognosis for Superficial thrombophlebitis is related to the underlying cause. In low-risk SVT, it is generally favorable, but there is a definite risk for recurrent disease. In those with higher risk SVT, the overall prognosis is also positive with appropriate treatment. For those with SVT due to underlying malignancy, the prognosis is related to that of the causative process.

Complications

DVT and PE are significant complications of Superficial thrombophlebitis. Multiple studies have found concomitant DVT with SVT in 6-36% of patients. These same studies clinically suspected concomitant PE in 2-13%, and regular performance of lung scans revealed the rate of asymptomatic PE approached 33%.[3] Other retrospective studies from both primary and secondary/tertiary centers reported concomitant DVT or symptomatic PE on the initial presentation to be 25-30%. About 5-7% of these patients had symptomatic PE.[3][4] However, the incidence of coexisting PE increased to 17% with the use of a more rigorous screening process of asymptomatic patients.[4] Patients with thrombus up to 3 cm from the saphenofemoral junction should be treated for DVT, given that 14-70% progress to DVT.[4][5] 

Consultations

Consultation with a vascular surgeon may be sought in patients with Superficial thrombophlebitis who require anticoagulation but who have contraindications to anticoagulation. It may also be an option in those with recurrent SVT in the setting of chronic venous insufficiency.[2][3][6]

Hematology/oncology consultation may also be considered in patients with underlying thrombophilias or malignancies.[2]

Deterrence and Patient Education

Patients should be educated on the likelihood and significance of the propagation of disease and recurrence based on their risk factors. They should be advised of the need for further evaluation in the presence of migratory thrombophlebitis or if they are more than 40 years old at the time of their initial presentation and are without other risk factors for venous thromboembolic disease.

Pearls and Other Issues

Patients with superficial thrombophlebitis should have compressive ultrasonography of both the affected and contralateral limb to evaluate for concomitant venous thromboembolic disease.

Anticoagulation with fondaparinux 2.5 mg/day should be considered in patients with superficial thrombophlebitis in the lower extremity that is at least 5 cm in length; SVT proximal to the knee, especially within 10 cm of the saphenofemoral junction; the presence of severe symptoms; greater saphenous vein involvement; previous SVT/venous thromboembolic disease; active malignancy; or recent surgery.

Experts do not routinely recommend investigation for thrombophilia and underlying malignancy.

In patients with migratory thrombophlebitis, further investigations for visceral malignancy should ensue.

Enhancing Healthcare Team Outcomes

Given the incidence of concomitant venous thromboembolic disease and the possibility of extension, it is paramount for health care team members to recognize that superficial thrombophlebitis is no longer considered a benign entity.[1][2][3][4][5] Thus, if non-providers observe such symptoms, the concern can be brought to the attention of providers. Providers should have a low threshold to ultrasound both the affected and contralateral limb to evaluate for concurrent venous thromboembolic disease.[2][5][6] [Level 1] Then, providers should treat accordingly.[1][2][5][6][13] [Level 2] The patients may also require further evaluation for thrombophilias according to existing guidelines.[2][5] [Level 1] It is also important for the health care team to recognize that migratory thrombophlebitis requires further evaluation as it is a rare presentation of visceral malignancy.[6][9] [Level 5]


References

[1] Di Nisio M,Wichers IM,Middeldorp S, Treatment for superficial thrombophlebitis of the leg. The Cochrane database of systematic reviews. 2018 Feb 25;     [PubMed PMID: 29478266]
[2] Nasr H,Scriven JM, Superficial thrombophlebitis (superficial venous thrombosis). BMJ (Clinical research ed.). 2015 Jun 22;     [PubMed PMID: 26099257]
[3] Décousus H,Bertoletti L,Frappé P, Spontaneous acute superficial vein thrombosis of the legs: do we really need to treat? Journal of thrombosis and haemostasis : JTH. 2015 Jun;     [PubMed PMID: 26149029]
[4] Di Minno MN,Ambrosino P,Ambrosini F,Tremoli E,Di Minno G,Dentali F, Prevalence of deep vein thrombosis and pulmonary embolism in patients with superficial vein thrombosis: a systematic review and meta-analysis. Journal of thrombosis and haemostasis : JTH. 2016 May;     [PubMed PMID: 26845754]
[5] Tait C,Baglin T,Watson H,Laffan M,Makris M,Perry D,Keeling D, Guidelines on the investigation and management of venous thrombosis at unusual sites. British journal of haematology. 2012 Oct;     [PubMed PMID: 22881455]
[6] Scott G,Mahdi AJ,Alikhan R, Superficial vein thrombosis: a current approach to management. British journal of haematology. 2015 Mar;     [PubMed PMID: 25521017]
[7] Maddox RP,Seupaul RA, What Is the Most Effective Treatment of Superficial Thrombophlebitis? Annals of emergency medicine. 2016 May;     [PubMed PMID: 26707361]
[8] Di Nisio M,Peinemann F,Porreca E,Rutjes AW, Treatment for superficial infusion thrombophlebitis of the upper extremity. The Cochrane database of systematic reviews. 2015 Nov 20;     [PubMed PMID: 26588711]
[9] Varki A, Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood. 2007 Sep 15;     [PubMed PMID: 17496204]
[10] Diaconu C,Mateescu D,Bălăceanu A,Marcu M,Jianu V,Stănică A, Pancreatic cancer presenting with paraneoplastic thrombophlebitis--case report. Journal of medicine and life. 2010 Jan-Mar;     [PubMed PMID: 20302205]
[11] Pomero F,Di Minno MN,Tamburini Premunian E,Malato A,Pasca S,Barillari G,Fenoglio L,Siragusa S,Di Minno G,Ageno W,Dentali F, A clinical score to rule out the concomitant presence of deep vein thrombosis in patients presenting with superficial vein thrombosis: The ICARO study. Thrombosis research. 2015 Nov;     [PubMed PMID: 26421909]
[12] Frappé P,Brosse Q,Seffert B,Décousus H,Bertoletti L, Ruling out deep vein thrombosis in patients with superficial vein thrombosis: external validation of the ICARO score. Journal of thrombosis and thrombolysis. 2019 Jan     [PubMed PMID: 30317413]
[13] Werth S,Bauersachs R,Gerlach H,Rabe E,Schellong S,Beyer-Westendorf J, Superficial vein thrombosis treated for 45 days with rivaroxaban versus fondaparinux: rationale and design of the SURPRISE trial. Journal of thrombosis and thrombolysis. 2016 Aug;     [PubMed PMID: 26973347]
[14] Amano M,Shimizu T, Mondor's Disease: A Review of the Literature. Internal medicine (Tokyo, Japan). 2018 Sep 15;     [PubMed PMID: 29780120]
[15] Useche JN,de Castro AM,Galvis GE,Mantilla RA,Ariza A, Use of US in the evaluation of patients with symptoms of deep venous thrombosis of the lower extremities. Radiographics : a review publication of the Radiological Society of North America, Inc. 2008 Oct;     [PubMed PMID: 18936036]
[16] Hall LD,Dalton SR,Fillman EP,Dohse L,Elston DM, Re-examination of features to distinguish polyarteritis nodosa from superficial thrombophlebitis. The American Journal of dermatopathology. 2013 Jun;     [PubMed PMID: 23392132]
[17] Barnes RW,Wu KK,Hoak JC, Differentiation of superficial thrombophlebitis from lymphangitis by doppler ultrasound. Surgery, gynecology     [PubMed PMID: 936045]
[18] Taute BM,Melnyk H,Podhaisky H, [Alternative sonographic diagnoses in patients with clinical suspicion of deep vein thrombosis]. Medizinische Klinik (Munich, Germany : 1983). 2010 Sep;     [PubMed PMID: 20878299]
[19] Tian F,Mazurek KR,Malinak RN,Dean SM,Kaffenberger BH, Pseudocellulitis Need Not be Benign: Three Cases of Superficial Migratory Thrombophlebitis with     [PubMed PMID: 29399267]